TETs exhibit relatively high degrees of PD-L1 expression, with frequencies of 23–92% in thymomas and 36–100% in thymic carcinomas, an observation that provided a rationale for the investigation of immune checkpoint blockade in recurrent TETs [21]. The gene discussed is CD274; the disease is thymic carcinoma.